TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18940877

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16489099

Group type: COMPARATOR
Intervention: ABP + RAP inputs
Number of subjects: 42

Group type: COMPARATOR
Intervention: ABP + CVRI inputs
Number of subjects: 42
Study: 15055892

Group type: COMPARATOR
Intervention: Intramuscular treatment with clonidine 2 microg kg(‐1)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control treatment with saline
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Block treatment with clonidine 2 microg kg(‐1)
Number of subjects: 7
Study: 11245644

Group type: EXPERIMENTAL
Intervention: Ticlopidine pretreatment (before stenting)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Abciximab
Number of subjects: 1600
Study: 9335410

Group type: COMPARATOR
Intervention: benazepril, 10 mg, plus placebo (BZ10)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: benazepril, 10 mg, plus amlodipine, 2.5 mg (BZ10/AML2.5)
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: benazepril, 10 mg, plus amlodipine, 5 mg (BZ10/AML5)
Number of subjects: 448
Study: 8227238

Group type: EXPERIMENTAL
Intervention: Mailed medication-refill reminders
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Unit-of-use packaging
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Combination of mailed medication-refill reminders and unit-of-use packaging
Number of subjects: 258

Group type: COMPARATOR
Intervention: Standard pharmaceutical care (Control)
Number of subjects: 258
Study: 3804025

Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (0.5 mg/patch)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Combination of transdermal scopolamine and cimetidine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31769592

Group type: EXPERIMENTAL
Intervention: Postexercise cooling (fan turned on during recovery)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no cooling during recovery)
Number of subjects: 48
Study: 31281558

Group type: EXPERIMENTAL
Intervention: Deep Slow Breathing (DSB) program for 6 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 28392320

Group type: EXPERIMENTAL
Intervention: Adenosine 5'-monophosphate (AMP)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Adenosine 5'-triphosphate (ATP)
Number of subjects: 10
Study: 26241865

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 73
Study: 24047486

Group type: COMPARATOR
Intervention: Conventional medical therapy (CMT)
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillators (ICD)
Number of subjects: 995
Study: 21558517

Group type: EXPERIMENTAL
Intervention: Intravenous epoetin alfa (60,000 U)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 222
Study: 19299145

Group type: EXPERIMENTAL
Intervention: Intra-articular cocktail analgesic injection (morphine, bupivacaine, betamethasone)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Intra-articular cocktail analgesic injection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (Control Group)
Number of subjects: 80
Study: 15894410

Group type: EXPERIMENTAL
Intervention: Genetic forms of Alzheimer's disease
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Genetic forms of Alzheimer's disease with presenilin-1 mutations
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sporadic cases of Alzheimer's disease
Number of subjects: 49

Group type: COMPARATOR
Intervention: Non-diseased controls
Number of subjects: 49
Study: 15545167

Group type: EXPERIMENTAL
Intervention: Seal oil (10 ml, self-administered through a nasoduodenal feeding tube 3 times daily for 10 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Soy oil (10 ml, self-administered through a nasoduodenal feeding tube 3 times daily for 10 days)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Seal oil
Number of subjects: 19
Study: 10896698

Group type: EXPERIMENTAL
Intervention: Total plasma homocysteine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Serum, red cell, and CSF folate, CSF S‐adenosylmethionine, and CSF monoamine metabolites
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (18 healthy volunteers and 20 patients with neurological disorders)
Number of subjects: 46
Study: 8761384

Group type: EXPERIMENTAL
Intervention: Elactocin (various infusion schedules: 1 h infusion 3 weekly, 24 h infusion 3 weekly, 1 h infusion daily x 5 (3 weekly), 1 h infusion weekly, continuous 5 day intravenous infusion)
Number of subjects: 0
Study: 1345261

Group type: EXPERIMENTAL
Intervention: Enalapril (E)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (H)
Number of subjects: 28
Study: 2865326

Group type: EXPERIMENTAL
Intervention: 7.5 mg of clorazepate at bedtime for two weeks
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 3033815

Group type: EXPERIMENTAL
Intervention: Wheat bran
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29746386

Group type: EXPERIMENTAL
Intervention: HIIT-T
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: HIIT-WB
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: MICT
Number of subjects: 55

Group type: COMPARATOR
Intervention: HIIT-T and MICT
Number of subjects: 55
Study: 28152984

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy within 2 months
Number of subjects: 210

Group type: COMPARATOR
Intervention: Watchful waiting (surgery after 12 months)
Number of subjects: 210
Study: 24716586

Group type: EXPERIMENTAL
Intervention: tofacitinib 2, 5 or 15mg twice daily
Number of subjects: 197

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 197
Study: 23264068

Group type: EXPERIMENTAL
Intervention: Goal Directed Therapy (GDT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 38
Study: 22035053

Group type: EXPERIMENTAL
Intervention: Caloric restriction only (CR, N = 9)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Caloric restriction plus moderate‐intensity aerobic exercise (CRM, N = 13)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Caloric restriction plus vigorous‐intensity aerobic exercise (CRV, N = 8)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined CRM and CRV (CRM+CRV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Caloric restriction only (CR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Caloric restriction plus moderate‐intensity aerobic exercise (CRM) and caloric restriction plus vigorous‐intensity aerobic exercise (CRV)
Number of subjects: 30
Study: 18481290

Group type: EXPERIMENTAL
Intervention: 0.5 mg BHT‐3009
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 267
Study: 16514109

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (nasal, 4 L . min(‐1))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Compressed air
Number of subjects: 9
Study: 14696019

Group type: EXPERIMENTAL
Intervention: Melatonin (3 weeks)
Number of subjects: 653

Group type: COMPARATOR
Intervention: Placebo (2 weeks)
Number of subjects: 653

Group type: COMPARATOR
Intervention: Placebo (1 week baseline followed by 3 weeks treatment)
Number of subjects: 653
Study: 11136301

Group type: EXPERIMENTAL
Intervention: Cilnidipine 10 mg orally for 7 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 10
Study: 9196517

Group type: EXPERIMENTAL
Intervention: BAYx 1005
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1348226

Group type: EXPERIMENTAL
Intervention: Rehabilitation group (R), n = 119
Number of subjects: 228

Group type: COMPARATOR
Intervention: Hospital group (H), n = 109 (Control)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Rehabilitation group (R)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Hospital group (H)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 228
Study: 4061800

Group type: EXPERIMENTAL
Intervention: Diazepam 0.75 mg/kg rectally
Number of subjects: 208

Group type: COMPARATOR
Intervention: Mixture of diazepam 0.5 mg/kg, morphine 0.15 mg/kg, and hyoscine 0.01 mg/kg rectally
Number of subjects: 208
Study: 30573298

Group type: EXPERIMENTAL
Intervention: CMC-GLY (carboxymethylcellulose 1.0% and glycerin 0.9%)
Number of subjects: 188

Group type: COMPARATOR
Intervention: CMC (carboxymethylcellulose 1.0%)
Number of subjects: 188
Study: 29098286

Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 607

Group type: COMPARATOR
Intervention: Topical medications
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Local Eye subscale of SHPC-18
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: Visual Function subscale of SHPC-18
Number of subjects: 607

Group type: EXPERIMENTAL
Intervention: SHPC-18
Number of subjects: 607
Study: 24528667

Group type: EXPERIMENTAL
Intervention: Whole body resistance exercise leading to failure (3 sets with 8RM load)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Whole body resistance exercise not to failure (3 sets with 70% of 8RM load)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Whole body resistance exercise leading to failure
Number of subjects: 14

Group type: COMPARATOR
Intervention: Non-exercise control session (30 min of seated rest)
Number of subjects: 14
Study: 23324103

Group type: EXPERIMENTAL
Intervention: Low protein diet
Number of subjects: 72

Group type: COMPARATOR
Intervention: Normal protein diet
Number of subjects: 72
Study: 21213114

Group type: EXPERIMENTAL
Intervention: Calcium carbonate chew
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milk mineral chew
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milk drink
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo chew
Number of subjects: 0
Study: 19743516

Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (ATRA) for remission induction and/or maintenance
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional chemotherapy (no ATRA)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: All patients (both ATRA and conventional chemotherapy)
Number of subjects: 53
Study: 17385465

Group type: EXPERIMENTAL
Intervention: Standard medication and free-load bicycle exercise (FBE)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard medication only
Number of subjects: 185

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 185
Study: 15078738

Group type: EXPERIMENTAL
Intervention: Anaerobic training (2 days per week for 12 weeks, 30 to 45 min per session, anaerobic activities lasting 20 to 30 s)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Anaerobic training (after 12-week follow-up)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no change in normal daily activities)
Number of subjects: 20
Study: 11802462

Group type: EXPERIMENTAL
Intervention: Johnson & Johnson Health & Wellness Program
Number of subjects: 0
Study: 9696444

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 40
Study: 7647718

Group type: EXPERIMENTAL
Intervention: Depressed pain patients
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Non-depressed pain patients
Number of subjects: 3

Group type: COMPARATOR
Intervention: Non-pain control subjects
Number of subjects: 3
Study: 2754771

Group type: EXPERIMENTAL
Intervention: Neonatal tetanus vaccination during pregnancy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Birth weight as an indicator
Number of subjects: 0
Study: 371317

Group type: EXPERIMENTAL
Intervention: Dexon
Number of subjects: 20

Group type: COMPARATOR
Intervention: chromic catgut-Mersilene
Number of subjects: 20
Study: 31823482

Group type: EXPERIMENTAL
Intervention: Hybrid trial designs combining RCTs and RWD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hybrid trial designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RWE from observational studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RWE
Number of subjects: 0
Study: 31399742

Group type: EXPERIMENTAL
Intervention: High cyclic temperature group (HT, 29‐35°C, ad libitum)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Thermoneutral group (TC, 21 ± 1°C, ad libitum)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Pair-feeding group (PF, 21 ± 1°C, pair-feeding on the daily feed intake of HT hens)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Correlation between feed intake and principal coordinate 1 (PC1) in PCoA
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Linear discriminant analysis
Number of subjects: 216
Study: 28085913

Group type: EXPERIMENTAL
Intervention: Physical training and nutrition group (PTN, n = 39)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Social support group (SoSu, n = 41)
Number of subjects: 80
Study: 26047409

Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative neurological deterioration
Number of subjects: 0
Study: 24053695

Group type: EXPERIMENTAL
Intervention: Ecologically valid strategy training
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 100
Study: 21355814

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg once daily
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg once daily
Number of subjects: 890

Group type: EXPERIMENTAL
Intervention: tolterodine extended release 4 mg
Number of subjects: 890

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 890
Study: 19954554

Group type: EXPERIMENTAL
Intervention: ICG‐PDR measured on day 1 in patients recovering spontaneously
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: ICG‐PDR measured on day 1 in patients not recovering spontaneously
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: ICG‐PDR value <= 6.3%/min on study day 1
Number of subjects: 25
Study: 17685714

Group type: EXPERIMENTAL
Intervention: Aerobic and muscular strength training program (12 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (dance-only approach)
Number of subjects: 32
Study: 15119879

Group type: EXPERIMENTAL
Intervention: Dual-cured resin composite
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Chemically cured resin composite
Number of subjects: 27
Study: 11317662

Group type: EXPERIMENTAL
Intervention: Saturated fatty acid diet (SAFA diet)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid diet (MUFA diet)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Saturated fatty acid diet (SAFA diet) with low fat intake (< 37E%)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acid diet (MUFA diet) with low fat intake (< 37E%)
Number of subjects: 162
Study: 9036909

Group type: EXPERIMENTAL
Intervention: Rehabilitation program in acute medical care of the elderly
Number of subjects: 0
Study: 7932162

Group type: EXPERIMENTAL
Intervention: Cocaine (30 mg i.v.)
Number of subjects: 8
Study: 2894547

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 29629852

Group type: EXPERIMENTAL
Intervention: Raltegravir 400 mg twice a day
Number of subjects: 44

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir 400/100 mg twice a day plus zidovudine and lamivudine
Number of subjects: 44
Study: 29658256

Group type: EXPERIMENTAL
Intervention: Bushen Daozhuo Granules (BDG) at 200 ml bid for 4 weeks
Number of subjects: 478

Group type: COMPARATOR
Intervention: Tamsulosin hydrochloride sustained-release capsules at 0.2 mg qd for 4 weeks
Number of subjects: 478
Study: 26548691

Group type: EXPERIMENTAL
Intervention: Printed material intervention
Number of subjects: 373

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 373
Study: 23959207

Group type: EXPERIMENTAL
Intervention: Self-paced walking intervention (WI): 3 sessions per week for 4 weeks on a predetermined variable topographic course.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CG): 30-minute stationary cycling, 3 sessions per week for 4 weeks.
Number of subjects: 22
Study: 21150167

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 67

Group type: COMPARATOR
Intervention: Vehicle cream (control)
Number of subjects: 67
Study: 18191683

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 18686
Study: 16613209

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study: 12895211

Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mesalamine
Number of subjects: 0
Study: 11118461

Group type: EXPERIMENTAL
Intervention: Combination of subcutaneous recombinant interleukin‐2 (rIL‐2) and recombinant interferon alfa‐2a (rIFNalpha‐2a)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Combination of subcutaneous recombinant interleukin‐2 (rIL‐2) and recombinant interferon alfa‐2a (rIFNalpha‐2a) with continuous infusion of fluorouracil (FU)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Both arms (A and B)
Number of subjects: 131
Study: 9167507

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 59
Study: 7507638

Group type: EXPERIMENTAL
Intervention: diltiazem 120 or 240 mg/day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: metoprolol 100 or 200 mg/day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: enalapril 10 or 20 mg/day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide 50 or 100 mg/day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: diltiazem and metoprolol in patients with >= 5 VPCs/hour at baseline
Number of subjects: 31
Study: 2924990

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parenteral pethidine
Number of subjects: 0
Study: 1092284

Group type: EXPERIMENTAL
Intervention: Metaproterenol sulfate combined with chlordiazepoxide hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlordiazepoxide hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30903540

Group type: EXPERIMENTAL
Intervention: Incremental theory intervention (n=456)
Number of subjects: 867

Group type: COMPARATOR
Intervention: Educational control intervention (n=411)
Number of subjects: 867
Study: 28340446

Group type: EXPERIMENTAL
Intervention: Behavioral weight loss interventions
Number of subjects: 409
Study: 25419871

Group type: EXPERIMENTAL
Intervention: Community health worker home visits (mean of 4.9 visits over 1 year)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 366
Study: 24021043

Group type: EXPERIMENTAL
Intervention: Nystatin 1000 kU three times a day via gastric tube
Number of subjects: 124

Group type: COMPARATOR
Intervention: Gastrointestinal prokinetic drug (placebo)
Number of subjects: 124
Study: 21741344

Group type: EXPERIMENTAL
Intervention: Deferasirox treatment for at least 3 years
Number of subjects: 219
Study: 19466986

Group type: EXPERIMENTAL
Intervention: Aspirin 80 mg (once daily for 7 days) + Diclofenac 50 mg (three times daily for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin 30 mg (once daily for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin 80 mg (once daily for 7 days) + Ibuprofen 800 mg (three times daily for 7 days)
Number of subjects: 0
Study: 19442346

Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 70
Study: 15257094

Group type: EXPERIMENTAL
Intervention: Selective p38 MAP kinase inhibitor drug, RWJ‐67657 (single oral dose administered 30 min before endotoxin infusion)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (single oral dose administered 30 min before endotoxin infusion)
Number of subjects: 21
Study: 11140429

Group type: EXPERIMENTAL
Intervention: CFC MDI (1000 microg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HFA MDI (1000 microg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous FP (250 microg)
Number of subjects: 12
Study: 7696060

Group type: EXPERIMENTAL
Intervention: Tracheal anaesthesia with i.v. fentanyl, propofol, atracurium and nitrous oxide
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Tracheal anaesthesia
Number of subjects: 82
Study: 2200555

Group type: EXPERIMENTAL
Intervention: Tamoxifen (30 mg daily)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Tamoxifen (for women in stage III)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo (for women in stage III)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Tamoxifen (for women after 2.5 years)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo (for women after 2.5 years)
Number of subjects: 176
Study: 7012398

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 100
Study: 30167752

Group type: EXPERIMENTAL
Intervention: FNB with posterior capsule injection (PCI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: FNB only
Number of subjects: 42
Study: 28388890

Group type: EXPERIMENTAL
Intervention: 1500 ml, 1000 ml, 500 ml, or 250 ml bottle sizes of cola
Number of subjects: 37
Study: 26044113

Group type: EXPERIMENTAL
Intervention: Reduction in PANSS total scores during a three-month period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10-point reductions in PANSS total score during three months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance of PANSS total score reduction for a year
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10-point reduction in PANSS total score
Number of subjects: 0
Study: 23996417

Group type: EXPERIMENTAL
Intervention: Cleaning with sodium hypochlorite wipes
Number of subjects: 59